Roughly two-thirds of patients categorized their experience with antipsychotics as more negative than positive and 34.9% endorsed an “extremely negative” experience.
Working memory is impaired in schizophrenia, and epigenetic mechanisms such as DNA methylation may contribute to illness risk.
Given the increased risk for opioid-related problems among patients with psychiatric diagnoses, the investigators advised a more cautious approach to prescribing that integrates expertise from mental health clinicians.
The results of the study point to the validity of the Research Domain Criteria initiative and suggest that neuroimaging findings may not be specific to certain psychiatric disorders.
Compared with patients without PTSD, patients with both bipolar disorder and PTSD were more likely to be women, on disability, have a lower education level, and have a lower annual household income.
Times between mood episodes longer for those in family-focused therapy versus enhanced usual care.
Among patients with borderline personality disorder, symptom severity was associated with less stability and lower relative amplitude. Impulsivity and mood instability were each negatively correlated with interdaily stability and relative amplitude.
The FDA has accepted for review the New Drug Application (NDA) for ALKS 3831 (Alkermes) for the treatment of schizophrenia and bipolar I disorder.
Taro Pharmaceuticals announced the voluntary recall of 1 lot of lamotrigine 100mg tablets to the consumer level due to cross-contamination with a small amount of enalapril maleate.
The findings suggest that factors such as antipsychotic treatment, diet, or lifestyle may contribute to weight gain in patients with long-term disease.